http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial
Keith Y. Terada,안형준,Bruce Kessel 대한부인종양학회 2016 Journal of Gynecologic Oncology Vol.27 No.3
Objective: To investigate the role of previous gynecologic surgery, hormone use, and use ofnon-steroidal anti-inflammatory drugs on the risk of type 1 and type 2 ovarian cancer. Methods: We utilized data collected for the Prostate, Lung, Colorectal, and Ovarian cancerscreening trial. All diagnosed ovarian cancers were divided into three groups: type 1,endometrioid, clear cell, mucinous, low grade serous, and low grade adenocarcinoma/nototherwise specified (NOS); type 2, high grade serous, undifferentiated, carcinosarcoma, andhigh grade adenocarcinoma/NOS; and other: adenocarcinoma with grade or histology notspecified, borderline tumors, granulosa cell tumors. The odds ratios for type 1, type 2, andother ovarian cancers were assessed with regard to historical information for specificrisk factors. Results: Ibuprofen use was associated with a decrease in risk for type 1 ovarian cancer. Tuballigation and oral contraceptive use were associated with a decrease in risk for type 2 ovariancancer. A history of ectopic pregnancy was associated with a decreased risk for all ovariancancers by almost 70%. Conclusion: These findings support the hypothesis that carcinogenic pathways for type 1 andtype 2 ovarian cancer are different and distinct. The marked reduction in all ovarian cancerrisk noted with a history of ectopic pregnancy and salpingectomy implies that the fallopiantube plays a key role in carcinogenesis for both type 1 and type 2 ovarian cancer.
Ovarian cancer screening in menopausal females with a family history of breast or ovarian cancer
Tiffany Lai,Bruce Kessel,Hyeong Jun Ahn,Keith Y. Terada 대한부인종양학회 2016 Journal of Gynecologic Oncology Vol.27 No.4
Objective: To determine whether annual screening reduces ovarian cancer mortality in women with a family history of breast or ovarian cancer. Methods: Data was obtained from the Prostate, Lung, Colorectal, and Ovarian cancer trial, a randomized multi-center trial conducted to determine if screening could reduce mortality in these cancers. The trial enrolled 78,216 women, randomized into either a screening arm with annual serum cancer antigen 125 and pelvic ultrasounds, or usual care arm. This study identified a subgroup that reported a first degree relative with breast or ovarian cancer. Analysis was performed to compare overall mortality and disease specific mortality in the screening versus usual care arm. In patients diagnosed with ovarian cancer, stage distribution, and survival were analyzed as a secondary endpoint. Results: There was no significant difference in overall mortality or disease specific mortality between the two arms. Ovarian cancer was diagnosed in 48 patients in the screening arm and 44 patients in the usual care arm. Screened patients were more likely to be diagnosed at an earlier stage than usual care patients. Patients in the screening arm diagnosed with ovarian cancer experienced a significantly improved survival compared to patients in the usual care arm; relative risk 0.66 (95% CI, 0.47 to 0.93). Conclusion: Screening did not appear to decrease ovarian cancer mortality in participants with a family history of breast or ovarian cancer. Secondary endpoints, however, showed notable differences. Significantly fewer patients were diagnosed with advanced stage disease in the screening arm; and survival was significantly improved. Further investigation is warranted to assess screening efficacy in women at increased risk.
Visible-wavelength spectroscopy of subkilometer-sized near-Earth asteroids with a low delta-v
Kuroda, D.,Ishiguro, M.,Takato, N.,Hasegawa, S.,Abe, M.,Tsuda, Y.,Sugita, S.,Usui, F.,Hattori, T.,Iwata, I.,Imanishi, M.,Terada, H.,Choi, Y.-J.,Watanabe, S.-i.,Yoshikawa, M. Astronomical Society of Japan 2014 Publications of the Astronomical Society of Japan Vol.66 No.3